Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus

Edén, 2010, HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment, J Infect Dis, 202, 1768, 10.1086/657342 Antinori, 2007, Updated research nosology for HIV-associated neurocognitive disorders, Neurology, 69, 1789, 10.1212/01.WNL.0000287431.88658.8b Heaton, 2010, HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study, Neurology, 75, 2087, 10.1212/WNL.0b013e318200d727 Canestri, 2010, Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy, Clin Infect Dis, 50, 773, 10.1086/650538 Johnson, 2010, Neurological complications of immune reconstitution in HIV-infected populations, Ann N Y Acad Sci, 1184, 106, 10.1111/j.1749-6632.2009.05111.x Letendre, 2008, Validation of the CNS penetration–effectiveness rank for quantifying antiretroviral penetration into the central nervous system, Arch Neurol, 65, 65, 10.1001/archneurol.2007.31 Tozzi, 2009, Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders, J Acquir Immune Defic Syndr, 52, 56, 10.1097/QAI.0b013e3181af83d6 Marra, 2009, Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance, AIDS, 23, 1359, 10.1097/QAD.0b013e32832c4152 Giancola, 2006, Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy, J Acquir Immune Defic Syndr, 41, 332, 10.1097/01.qai.0000197077.64021.07